Alnylam Pharmaceuticals, Inc. $ALNY Position Increased by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. raised its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 10.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 25,267 shares of the biopharmaceutical company’s stock after purchasing an additional 2,480 shares during the period. Alnylam Pharmaceuticals comprises about 0.8% of China Universal Asset Management Co. Ltd.’s portfolio, making the stock its 28th largest holding. China Universal Asset Management Co. Ltd.’s holdings in Alnylam Pharmaceuticals were worth $10,047,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in Alnylam Pharmaceuticals by 2.0% during the third quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock valued at $6,185,846,000 after purchasing an additional 268,313 shares during the last quarter. Capital Research Global Investors grew its position in shares of Alnylam Pharmaceuticals by 0.4% during the third quarter. Capital Research Global Investors now owns 7,222,840 shares of the biopharmaceutical company’s stock worth $3,293,516,000 after acquiring an additional 31,184 shares during the last quarter. Groupama Asset Managment grew its position in shares of Alnylam Pharmaceuticals by 160.4% during the third quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock worth $18,610,000 after acquiring an additional 2,483,697 shares during the last quarter. Orbis Allan Gray Ltd grew its position in shares of Alnylam Pharmaceuticals by 29.8% during the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after acquiring an additional 486,489 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its position in shares of Alnylam Pharmaceuticals by 698.8% during the third quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock worth $618,158,000 after acquiring an additional 1,185,909 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Kevin Joseph Fitzgerald sold 1,652 shares of the company’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $319.73, for a total value of $528,193.96. Following the completion of the sale, the executive vice president owned 21,860 shares of the company’s stock, valued at $6,989,297.80. This represents a 7.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Melissa Mclaughlin sold 2,286 shares of the company’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $330.42, for a total transaction of $755,340.12. Following the completion of the sale, the insider directly owned 9,443 shares of the company’s stock, valued at $3,120,156.06. The trade was a 19.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 38,656 shares of company stock valued at $12,370,696. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

ALNY stock opened at $313.79 on Friday. The company has a market capitalization of $41.87 billion, a P/E ratio of 183.50 and a beta of 0.39. The company has a 50-day simple moving average of $322.25 and a 200 day simple moving average of $382.67. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $238.62 and a fifty-two week high of $495.55. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.18). The company had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The business’s revenue for the quarter was up 84.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.65) EPS. Sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.75 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently commented on ALNY. Canaccord Genuity Group upped their price target on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. Raymond James Financial restated an “outperform” rating and set a $472.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, January 12th. Morgan Stanley lowered their price target on shares of Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating for the company in a research report on Friday, January 30th. Chardan Capital restated a “buy” rating and set a $425.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 25th. Finally, Freedom Capital upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 17th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $472.78.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.